Literature DB >> 22499079

Tobacco use treatment at the U.S. National Cancer Institute's designated Cancer Centers.

Adam O Goldstein1, Carol E Ripley-Moffitt, Donald E Pathman, Katharine M Patsakham.   

Abstract

INTRODUCTION: Tobacco use is a leading cause of cancer, and continued use after cancer diagnosis puts patients at greater risk for adverse health outcomes, including increased risk for cancer recurrence. This study surveyed National Cancer Institute (NCI)-designated Cancer Centers to assess the availability of tobacco use treatment (TUT) services.
METHODS: Directors and oncology providers of 58 NCI-designated Cancer Centers received invitations to participate in an online survey. The questionnaire asked about attitudes, awareness, policies, and practices related to TUT; barriers to treatment provision; and factors likely to increase services.
RESULTS: All 58 Cancer Centers participated. Twelve (20.7%) Centers reported no TUT services for their patients. Of the remainder, 34 (58.6%) reported a TUT program within their Center and 12 (20.7%) reported external TUT services in their health care system or affiliated university. Only 62% of Centers reported routinely providing tobacco education materials to patients, just over half reported effective identification of patient tobacco use, and less than half reported an employee dedicated to providing TUT services or a clear commitment to providing TUT services from Center leadership. The 34 centers with internal TUT programs reported significantly greater services and administration support for TUT Services.
CONCLUSIONS: These data demonstrate a national need for Cancer Centers to embrace and incorporate recommended standards for TUT. Tying TUT services to NCI recognition and providing stable funding for TUT services in Cancer Centers could lead to better health outcomes, treatment efficacy, and satisfaction for all U.S. Cancer Centers and their patients.

Entities:  

Mesh:

Year:  2012        PMID: 22499079      PMCID: PMC3842130          DOI: 10.1093/ntr/nts083

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  15 in total

1.  Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder.

Authors:  N Fleshner; J Garland; A Moadel; H Herr; J Ostroff; R Trambert; M O'Sullivan; P Russo
Journal:  Cancer       Date:  1999-12-01       Impact factor: 6.860

2.  Longitudinal predictors of continued tobacco use among patients diagnosed with cancer.

Authors:  Robert A Schnoll; Calvin James; Michael Malstrom; Randi L Rothman; Hao Wang; James Babb; Suzanne M Miller; John A Ridge; Benjamin Movsas; Corey Langer; Michael Unger; Melvyn Goldberg
Journal:  Ann Behav Med       Date:  2003

3.  Smoking cessation for hospitalized smokers: an evaluation of the "Ottawa Model".

Authors:  Robert D Reid; Kerri-Anne Mullen; Monika E Slovinec D'Angelo; Debbie A Aitken; Sophia Papadakis; Patricia M Haley; Christine A McLaughlin; Andrew L Pipe
Journal:  Nicotine Tob Res       Date:  2009-11-10       Impact factor: 4.244

4.  The relationship between cigarette smoking and quality of life after lung cancer diagnosis.

Authors:  Yolanda I Garces; Ping Yang; Julia Parkinson; Xinghua Zhao; Jason A Wampfler; Jon O Ebbert; Jeff A Sloan
Journal:  Chest       Date:  2004-12       Impact factor: 9.410

5.  A qualitative study of increasing beta-blocker use after myocardial infarction: Why do some hospitals succeed?

Authors:  E H Bradley; E S Holmboe; J A Mattera; S A Roumanis; M J Radford; H M Krumholz
Journal:  JAMA       Date:  2001 May 23-30       Impact factor: 56.272

6.  Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies.

Authors:  Kim-Anh Do; Marcella M Johnson; J Jack Lee; Xi Feng Wu; Qiong Dong; Waun K Hong; Fadlo R Khuri; Margaret R Spitz
Journal:  Cancer       Date:  2004-12-15       Impact factor: 6.860

7.  Tobacco use outcomes among patients with lung cancer treated for nicotine dependence.

Authors:  Lisa Sanderson Cox; Christi A Patten; Jon O Ebbert; Amanda A Drews; Gary A Croghan; Matthew M Clark; Troy D Wolter; Paul A Decker; Richard D Hurt
Journal:  J Clin Oncol       Date:  2002-08-15       Impact factor: 44.544

8.  Treating tobacco dependence in a medical setting.

Authors:  Richard D Hurt; Jon O Ebbert; J Taylor Hays; David D McFadden
Journal:  CA Cancer J Clin       Date:  2009-08-25       Impact factor: 508.702

9.  Smoking as a vital sign: prompts to ask and assess increase cessation counseling.

Authors:  Anna McCullough; Michael Fisher; Adam O Goldstein; Kathryn D Kramer; Carol Ripley-Moffitt
Journal:  J Am Board Fam Med       Date:  2009 Nov-Dec       Impact factor: 2.657

Review 10.  Second lung cancers in patients after treatment for an initial lung cancer.

Authors:  B E Johnson
Journal:  J Natl Cancer Inst       Date:  1998-09-16       Impact factor: 13.506

View more
  43 in total

1.  Smoking and Smoking Cessation Among Persons with Tobacco- and Non-tobacco-Associated Cancers.

Authors:  M Shayne Gallaway; Bin Huang; Quan Chen; Thomas C Tucker; Jaclyn K McDowell; Eric Durbin; Sherri L Stewart; Eric Tai
Journal:  J Community Health       Date:  2019-06

2.  Electronic cigarette use among patients with cancer: characteristics of electronic cigarette users and their smoking cessation outcomes.

Authors:  Sarah P Borderud; Yuelin Li; Jack E Burkhalter; Christine E Sheffer; Jamie S Ostroff
Journal:  Cancer       Date:  2014-09-22       Impact factor: 6.860

3.  Smoking Cessation Support Among Oncology Practitioners in a Regional Cancer Center in the Middle East-Improving a Critical Service for Cancer Care.

Authors:  Nour A Obeidat; Hiba S Ayub; Rula Amarin; Barakat Aburajab Altamimi; Iyad Ghonimat; Susan Abughosh; Feras I Hawari
Journal:  Oncologist       Date:  2016-03-09

4.  Educational Needs of Oncology Practitioners in a Regional Cancer Center in the Middle East-Improving the Content of Smoking Cessation Training Programs.

Authors:  N A Obeidat; F I Hawari; R Amarin; B Aburajab Altamimi; I M Ghonimat
Journal:  J Cancer Educ       Date:  2017-12       Impact factor: 2.037

5.  Building Systems to Address Tobacco Use in Oncology: Early Benefits and Opportunities From the Cancer Center Cessation Initiative.

Authors:  Brian P Jenssen; Frank Leone; Sarah Evers-Casey; Rinad Beidas; Robert Schnoll
Journal:  J Natl Compr Canc Netw       Date:  2019-06-01       Impact factor: 11.908

Review 6.  Tobacco Use Assessment and Treatment in Cancer Patients: A Scoping Review of Oncology Care Clinician Adherence to Clinical Practice Guidelines in the U.S.

Authors:  Sarah N Price; Jamie L Studts; Heidi A Hamann
Journal:  Oncologist       Date:  2018-11-16

7.  Perspective on the National Comprehensive Cancer Network's Clinical Practice Guidelines for Smoking Cessation.

Authors:  Jamie S Ostroff; John R Goffin; Fadlo R Khuri; Graham W Warren
Journal:  J Oncol Pract       Date:  2015-09-15       Impact factor: 3.840

8.  Pilot randomized controlled trial of a comprehensive smoking cessation intervention for patients with upper aerodigestive cancer undergoing radiotherapy.

Authors:  Eleni M Rettig; Carole Fakhry; Russell K Hales; Flora Kisuule; Harry Quon; Ana P Kiess; Linda X Yin; Yuehan Zhang; Amanda L Blackford; M Bradley Drummond; Christine G Gourin; Wayne M Koch; David W Eisele; Gypsyamber D'Souza
Journal:  Head Neck       Date:  2018-03-15       Impact factor: 3.147

9.  Practice patterns and perceptions of thoracic oncology providers on tobacco use and cessation in cancer patients.

Authors:  Graham W Warren; James R Marshall; K Michael Cummings; Benjamin Toll; Ellen R Gritz; Alan Hutson; Seyedeh Dibaj; Roy Herbst; Carolyn Dresler
Journal:  J Thorac Oncol       Date:  2013-05       Impact factor: 15.609

10.  Tobacco use in the oncology setting: advancing clinical practice and research.

Authors:  Ellen R Gritz; Benjamin A Toll; Graham W Warren
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-01       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.